Rocket Pharmaceuticals (RCKT) Other Non-Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals has reported Other Non-Current Liabilities for 13 years, with the latest figure at $1.1 million in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 6.92% year-over-year to $1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 6.92% YoY) and the FY2025 annual result came in at $1.1 million, down 7.1% from the prior year.
• Other Non-Current Liabilities was little changed at $1.1 million in Q1 2026 per RCKT's latest filing, from $1.1 million in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $2.9 million in Q4 2023 and troughed at $37000.0 in Q3 2022.
• A 5-year average of $1.3 million and a median of $1.1 million in 2024 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities soared 4951.35% in 2023, then sank 61.14% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $2.6 million in 2022, then increased by 13.14% to $2.9 million in 2023, then tumbled by 61.14% to $1.1 million in 2024, then slipped by 7.1% to $1.1 million in 2025, then rose by 0.19% to $1.1 million in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $1.1 million, $1.1 million, and $1.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.